conformation, acylketenes behave almost exclusively as 1,3-
oxadienes in inverse demand hetero-Diels-Alder reactions.9
Examples of [2 + 2] cycloadditions to the ketene function
of acylketenes are rare, and with the exception of their
cyclodimerization, examples of 6π electrocyclic events
involving the CdC bond of acylketenes as dienophiles are
unknown.8 We report herein that under microwave irradiation
in situ generated 1-azadienes10 react smoothly with cyclic
acylketene dienophiles Via [2 + 4] cycloaddition to produce
diastereoselectively a variety of R-spiro-δ-lactams in a single
multiple bond-forming transformation.11,12
We recently became interested in applications of the
microwave-assisted Wolff rearrangement13 of 2-diazo-cy-
cloalkan-1,3-diones as a very convenient source of cyclic
acylketenes,14 notably a three-component approach to 1,3-
oxazin-4-ones involving the in situ formation of the dieno-
philic CdN double bond.14b The projected extension of this
methodology to 2-vinyl-1,3-oxazin-4-ones (e.g., 8a) using
R,ꢀ-unsaturated aldehydes has revealed an unprecedented
periselectivity switch of acylketenes. The microwave irradia-
tion at 140 °C for 15 min of a 1:1:1 mixture of the diazo
compound 1a, benzylamine (2a), and cinnamaldehyde (3a)
unexpectedly furnished the R-spiro-δ-lactam product 4a as
a single diastereomer in 74% yield, resulting from a formal
[2 + 4] cycloaddition between the CdC bond of the
acylketene 5a as dienophile and the 1-azadiene 6a generated
in situ (Scheme 1). As anticipated, the formation of the
believed to involve first the reversible formation of the
zwitterionic intermediates 7exo and 7endo. The second step,
which can be viewed as a reversible six-electron disrotatory
electrocyclization, would lead to the spiro compound 4a from
7exo, whereas the oxazinone 8a would derive from 7endo. From
these considerations, the periselectivity of the reaction, i.e.,
[2 + 4] versus [4 + 2] cyclization, would be determined by
the relative enthalpies of formation of the two compounds
4a and 8a, respectively, with preferential formation of the
former.15 The reversible formation of 2-vinyl-1,3-oxazin-
4-ones 8 as depicted in Scheme 1 was unambiguously
demonstrated: oxazinone 8j obtained as a minor byproduct
when the reaction of entry 9 (Table 1) is performed at 140
°C (Vide infra) was converted into the spiro product 4j
(conversion 100%, isolated yield 25%) together with 2-me-
thylcinnamaldehyde (ca. 20%) and degradation after 15 min
at 160 °C. A 3,3-sigmatropic rearrangement, which could
also account for the conversion of 8j into 4j, is not consistent
with the observed regeneration of the aldehyde under the
reaction conditions.
Spiro compounds are of broad scientific interest due to
their unique chemical and conformational features as well
as the biological properties often associated with the asym-
metric spiro carbon atom. They have attracted considerable
attention from the synthetic community.16 In the case of
complex bioactive molecules containing a spiranic subunit,
it often occurs that simplified analogues retaining essentially
the spiro structural domain exhibit a comparable, and
sometimes better, biological profile as the parent com-
pounds.17 With in mind the application of this new reaction
to the synthesis of hitherto unknown small bioactive R-spiro-
δ-lactam molecules,18 we explored its scope and limits.
Scheme 1
.
Periselectivity Switch of Acylketenes in 6π
Electrocyclizations
(11) For a complementary synthetic approach to R-spirolactams involv-
ing a single multiple-bond forming reaction, see: Boddaert, T.; Coquerel,
Y.; Rodriguez, J. AdV. Synth. Catal. 2009, 351, 1744.
(12) For reviews on multicomponent reactions with 1,3-dicarbonyls, see:
(a) Simon, C.; Constantieux, T.; Rodriguez, J. Eur. J. Org. Chem. 2004,
4957. (b) Lie´by-Muller, F.; Simon, C.; Constantieux, T.; Rodriguez, J. QSAR
Comb. Sci. 2006, 5-6, 432. (c) Bonne, D.; Coquerel, Y.; Constantieux, T.;
Rodriguez, J. Tetrahedron: Asymmetry 2010, 21, 1085.
(13) Kirmse, W. Eur. J. Org. Chem. 2002, 2193.
(14) (a) Presset, M.; Coquerel, Y.; Rodriguez, J. J. Org. Chem. 2009,
74, 415. (b) Presset, M.; Coquerel, Y.; Rodriguez, J. Org. Lett. 2009, 11,
5706.
(15) The enthalpies of formation obtained from DFT (B3LYP/6-311G**)
calculations (Gaussian) showed a preference of 9.9 kcal/mol for the
formation of the R-spiro-δ-lactam product 4 over the 2-vinyl-1,3-oxazin-
4-one product 8 from methylamine, aldehyde 3a, and the diazo compound
1c. A full theoretical study (DFT) of the periselectivities in acylketene
cycloadditions is in progress and will be reported in due time.
(16) (a) Sannigrahi, M. Tetrahedron 1999, 55, 9007. (b) Pradhan, R.;
Patra, M.; Behera, A. K.; Mishra, B. K.; Behera, R. K. Tetrahedron 2006,
62, 779. (c) Sinibaldi, M.-E.; Canet, I. Eur. J. Org. Chem. 2008, 4391. (d)
Raju, B. R.; Saikia, A. K. Molecules 2008, 13, 1942. (e) Kotha, S.; Deb,
A. C.; Lahiri, K.; Manivannan, E. Synthesis 2009, 165.
1-azadiene is faster than the formation of the acylketene by
Wolff rearrangement under the reaction conditions, thus
avoiding the nucleophilic addition of the amine to the
acylketene leading to a ꢀ-ketoamide product.14a According
to the stepwise mechanism generally admitted for the
Staudinger reaction, the reaction presented in Scheme 1 is
(17) Nicolaou, K. C.; Wu, T. R.; Sarlah, D.; Shaw, D. M.; Rowcliffe,
E.; Burton, D. R. J. Am. Chem. Soc. 2008, 130, 11114.
(8) (a) Wentrup, C.; Heilmayer, W.; Kollenz, G. Synthesis 1994, 1219.
(b) Kollenz, G.; Ebner, S. In Science of Synthesis: Houben-Weyl Methods
of Molecular Transformations; Danheiser, R., Ed.; Georg Thieme Verlag:
Stuttgart, Germany, 2006, Vol. 23, Chapter 9, pp 271-349. (c) Reber, K. P.;
Tilley, S. D.; Sorensen, E. J. Chem. Soc. ReV. 2009, 38, 3022.
(9) Birney, D. M.; Wagenseller, P. E. J. Am. Chem. Soc. 1994, 116,
6262.
(18) For recent representative examples of de novo biologically active
R-spiro-δ-lactams, see: (a) Craig, C. A. (Merck & Co) WO-A1 2010033421,
2010. (b) Selnick, H. G.; Bell, I. M.; Mcwherter, M.; Staas, D. D.; Stachel,
S. J.; Steele, T.; Stump, C.; Wood, M. R.; Zartman, C. B. (Merck & Co)
WO-A2 2009120652, 2009. (c) Nakagawa, A.; Uno, S.; Makishima, M.;
Miyachi, H.; Hashimoto, Y. Bioorg. Med. Chem. 2008, 16, 7046. (d) Meng,
X.; Maggs, J. L.; Pryde, D. C.; Planken, S.; Jenkins, R. E.; Peakman, T. M.;
Beaumont, K.; Kohl, C.; Park, B. K.; Stachulski, A. V. J. Med. Chem. 2007,
50, 6165.
(10) Groenendaal, B.; Ruijter, E.; Orru, R. V. A. Chem. Commun. 2008,
5474.
Org. Lett., Vol. 12, No. 18, 2010
4213